Cargando…
Biosimilar insulins: guidance for data interpretation by clinicians and users
Biosimilar insulins are approved copies of insulins outside patent protection. Advantages may include greater market competition and potential cost reduction, but clinicians and users lack a clear perspective on ‘biosimilarity’ for insulins. The manufacturing processes for biosimilar insulins are ma...
Autores principales: | Heinemann, L., Home, P. D., Hompesch, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744724/ https://www.ncbi.nlm.nih.gov/pubmed/25974131 http://dx.doi.org/10.1111/dom.12491 |
Ejemplares similares
-
An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
por: Heinemann, Lutz, et al.
Publicado: (2015) -
Biosimilar Insulins – What a Clinician Needs to Know?
por: Ghosh, Sujoy, et al.
Publicado: (2019) -
Biosimilar insulins: a European perspective
por: DeVries, J H, et al.
Publicado: (2015) -
Biosimilars: potential implications for clinicians
por: Eleryan, Misty G, et al.
Publicado: (2016) -
How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
por: Triplitt, Curtis, et al.
Publicado: (2017)